Insight Molecular Diagnostics, Inc. (Nasdaq: IMDX), known as iMDx, is highlighting its leadership in transplant rejection testing at two key industry conferences this fall, with presentations focused on its GraftAssure(TM) technology and investigational kitted assays.

Focus on Surveillance and Response Monitoring

At the 23rd International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) annual meeting in Singapore, iMDx hosted a symposium showcasing how GraftAssure can be used not only to detect transplant rejection but also to monitor treatment response. The presentation highlighted previously published data demonstrating that the technology significantly reduces the time to diagnosis in certain high-risk kidney transplant patients.

"Kidney transplant management is changing," said Josh Riggs, CEO of iMDx. "Emerging medications such as anti-CD38 therapies have a chance at treating transplant rejection, and in-house testing will bring care where it belongs - closer to the patient. Our presentations this fall in both Singapore and Orlando highlight the bright potential of our technology and the strong global interest in our assay."

Advancing GraftAssureIQ in Orlando

Next, iMDx and its strategic partner Bio-Rad Laboratories will present at the 51st American Society of Histocompatibility and Immunogenetics (ASHI) annual meeting in Orlando on October 9. The session will focus on GraftAssureIQ, iMDx's research-use-only kitted test, and its potential to support broader in-house dd-cfDNA testing for transplant research.

Speakers include Dr. Ekke Schuetz, Chief Science Officer at iMDx, alongside Bio-Rad's Eric Johnson, PhD, and other scientific leaders.

"We are pleased to be able to communicate the value of our kitted test to the many thought leaders in transplant and diagnostics who will be at ASHI," said Dr. Schuetz. "Our goal is to enable precise and accessible in-house dd-cfDNA testing for hospitals and particularly their kidney transplant patients. Our ongoing study to support regulatory clearance of our clinical kitted assay is well underway, and we look forward to submitting GraftAssureDx for FDA review by year end."

Market Opportunity

GraftAssureIQ has been available for research use since 2024, while the clinical kitted version, GraftAssureDx, is currently in development. Both measure donor-derived cell-free DNA (dd-cfDNA), an established biomarker of transplant rejection. With an estimated $1 billion addressable market for kitted transplant rejection testing, iMDx sees its technology as a potential breakthrough in expanding access and improving outcomes for kidney transplant patients.

Conference Details

• IATDMCT 2025 (Singapore)
  Session: Donor-derived cell-free DNA for Personalized Immunosuppression in Transplantation
  Speakers: Michael Oellerich, MD; Klemens Budde, MD; Geoff Bien (iMDx)
  Date/Time: Wednesday, September 24, 12:30-1:25 pm SGT
• ASHI 2025 (Orlando, FL)
  Session: GraftAssureIQ: Enabling In-House dd-cfDNA Testing in Transplant Research
  Speakers: Ryan Andrews (iMDx); Eric Johnson, PhD (Bio-Rad); Geoff Bien (iMDx); Ekke Schuetz, MD, PhD (iMDx)
  Date/Time: Thursday, October 9, 12:40-1:35 pm ET

About Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics Inc., or iMDx, formerly Oncocyte Corp. (OCX), is a pioneering precision diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. iMDx utilizes a well-established proprietary approach to quantify dd-cfDNA, which is a widely used molecular biomarker of transplant rejection.

iMDx(TM), GraftAssure(TM), GraftAssureCore(TM), GraftAssureIQ(TM), GraftAssureDx(TM), and VitaGraft(TM) are trademarks of Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics (Nasdaq: IMDX) moved its headquarters from Irvine, Calif., to Nashville, Tenn., in June 2025. The company's new NASDAQ symbol became effective June 18. Investors may visit https://investors.imdxinc.com/ for more information.

This article contains sponsored content. Please see our disclaimer at: https://prismmarketview.com/disclaimer/

The post Insight Molecular Diagnostics Showcases Kidney Transplant Testing Leadership at Global Conferences appeared first on PRISM MarketView.

COMTEX_469016297/2927/2025-09-24T11:31:19